| Literature DB >> 30429512 |
Eri Miyamoto-Mikami1, Katsunori Tsuji2, Naoki Horii2, Natsuki Hasegawa2,3, Shumpei Fujie2,3, Toshiyuki Homma4, Masataka Uchida2, Takafumi Hamaoka5, Hiroaki Kanehisa1, Izumi Tabata2, Motoyuki Iemitsu6.
Abstract
High-intensity intermittent exercise training (HIIT) has been proposed as an effective approach for improving both, the aerobic and anaerobic exercise capacity. However, the detailed molecular response of the skeletal muscle to HIIT remains unknown. We examined the effects of the HIIT on the global gene expression in the human skeletal muscle. Eleven young healthy men participated in the study and completed a 6-week HIIT program involving exhaustive 6-7 sets of 20-s cycling periods with 10-s rests. In addition to determining the maximal oxygen uptake ([Formula: see text]), maximal accumulated oxygen deficit, and thigh muscle cross-sectional area (CSA), muscle biopsy samples were obtained from the vastus lateralis before and after the training to analyse the skeletal muscle transcriptome. The HIIT program significantly increased the [Formula: see text], maximal accumulated oxygen deficit, and thigh muscle CSA. The expression of 79 genes was significantly elevated (fold-change >1.2), and that of 73 genes was significantly reduced (fold-change <0.8) after HIIT. Gene ontology analysis of the up-regulated genes revealed that the significantly enriched categories were "glucose metabolism", "extracellular matrix", "angiogenesis", and "mitochondrial membrane". By providing information about a set of genes in the human skeletal muscle that responds to the HIIT, the study provided insight into the mechanism of skeletal muscle adaptation to HIIT.Entities:
Mesh:
Year: 2018 PMID: 30429512 PMCID: PMC6235852 DOI: 10.1038/s41598-018-35115-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Subject characteristics before and after the 6-week HIIT (n = 11).
| Before | After | ||
|---|---|---|---|
| Age (yr) | 23.3 ± 2.8 | — | |
| Height (cm) | 173.7 ± 7.2 | — | |
| Body weight (kg) | 67.1 ± 7.1 | 67.7 ± 6.8 | 0.303 |
| BMI | 22.2 ± 1.6 | 22.4 ± 1.4 | 0.264 |
| %fat (%) | 15.0 ± 1.7 | 15.6 ± 2.5 | 0.189 |
| Skeletal muscle mass (kg) | 32.4 ± 3.3 | 32.3 ± 3.2 | 0.821 |
| Quadriceps femoris CSA (mm2) | 7059.8 ± 924.8 | 7358.4 ± 977.7 |
|
| Hamstrings CSA (mm2) | 3512.8 ± 588.2 | 3594.3 ± 599.3 |
|
| Adductors CSA (mm2) | 3539.0 ± 793.4 | 3616.6 ± 830.1 | 0.435 |
| Total energy intake (kcal/day) | 2329.7 ± 719.6 | 2264.3 ± 766.9 | 0.446 |
| Protein intake (g/day) | 77.7 ± 27.2 | 77.7 ± 41.1 | 0.995 |
| Fat intake (g/day) | 64.2 ± 30.1 | 64.7 ± 37.4 | 0.913 |
| Carbohydrate intake (g/day) | 340.6 ± 98.6 | 318.6 ± 77.4 | 0.088 |
Values are presented as mean ± SD. CSA: cross-sectional area.
Figure 1Maximal oxygen uptake [absolute (a) and relative (b)] and maximal accumulated oxygen deficit [absolute (c) and relative (d)] before and after HIIT (n = 11). The 6-week HIIT intervention significantly increased and the maximal accumulated oxygen deficit. The bars represent means and SDs. : maximal oxygen uptake; MAOD: maximal accumulated oxygen deficit. *P < 0.05 vs. before-HIIT values.
Seventy-nine genes that were significantly up-regulated after 6-week HIIT.
| Gene symbol | Gene description | Expression value | Fold change | ||
|---|---|---|---|---|---|
| Before | After | ||||
|
| ADAM metallopeptidase with thrombospondin type 1 motif, 15 | 28.5 | 34.9 | 1.23 | 0.00146 |
|
| ATP synthase, H + transporting, mitochondrial Fo complex, subunit C3 (subunit 9) | 278.5 | 343.3 | 1.23 | 0.00013 |
|
| breast carcinoma amplified sequence 2 | 283.3 | 390.6 | 1.38 | 0.00050 |
|
| chromosome 2 open reading frame 57 | 30.8 | 37.5 | 1.22 | 0.00236 |
|
| chromosome 3 open reading frame 35 | 68.7 | 83.3 | 1.21 | 0.00030 |
|
| carbonic anhydrase XIV | 65.6 | 130.3 | 1.99 | 0.00022 |
|
| carnosine synthase 1 | 122.5 | 156.9 | 1.28 | 5.6E-05 |
|
| CD79a molecule, immunoglobulin-associated alpha | 60.8 | 98.3 | 1.62 | 3.4E-05 |
|
| creatine kinase, mitochondrial 2 (sarcomeric) | 933.8 | 1194.8 | 1.28 | 0.00044 |
|
| collagen, type IV, alpha 1 | 72.9 | 106.6 | 1.46 | 0.00022 |
|
| collagen, type IV, alpha 2 | 75.2 | 96.2 | 1.28 | 0.00059 |
|
| DENN/MADD domain containing 2C | 459.3 | 582.8 | 1.27 | 0.00142 |
|
| DNM1 pseudogene 35 | 62.4 | 76.3 | 1.22 | 0.00027 |
|
| destrin (actin depolymerizing factor) pseudogene 2 | 31.4 | 43.8 | 1.40 | 0.00147 |
|
| double homeobox 4 like 9 | 76.9 | 93.2 | 1.21 | 0.00187 |
|
| FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) | 61.2 | 81.8 | 1.34 | 0.00047 |
|
| fructose-1,6-bisphosphatase 2 | 1292.5 | 1726.0 | 1.34 | 1E-05 |
|
| fibroblast growth factor 6 | 43.9 | 59.5 | 1.35 | 2.5E-06 |
|
| FAM21B pseudogene | 41.6 | 52.3 | 1.26 | 0.00152 |
|
| G0/G1switch 2 | 448.4 | 644.1 | 1.44 | 0.00106 |
|
| glutamate decarboxylase-like 1 | 143.3 | 202.0 | 1.41 | 5.7E-05 |
|
| glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) | 1324.3 | 1612.1 | 1.22 | 0.00105 |
|
| histone cluster 3, H2bb | 57.8 | 69.7 | 1.21 | 0.00125 |
|
| iroquoishomeobox 3 | 96.6 | 117.3 | 1.21 | 0.00013 |
|
| kinase insert domain receptor (a type III receptor tyrosine kinase) | 69.3 | 90.6 | 1.31 | 0.00022 |
|
| laminin, beta 1 | 56.4 | 82.2 | 1.46 | 9.1E-05 |
|
| uncharacterized LOC100131174 | 103.1 | 251.6 | 2.44 | 1.5E-05 |
|
| uncharacterized LOC100506114 | 662.2 | 876.1 | 1.32 | 0.00063 |
|
| actin, alpha 2, smooth muscle, aorta pseudogene | 32.5 | 40.5 | 1.25 | 0.00053 |
|
| latexin | 39.6 | 48.8 | 1.23 | 0.00215 |
|
| malate dehydrogenase 1, NAD (soluble) | 555.5 | 671.4 | 1.21 | 0.00037 |
|
| microRNA 106b | 50.2 | 60.8 | 1.21 | 0.00186 |
|
| microRNA 346 | 116.6 | 143.7 | 1.23 | 0.00017 |
|
| microRNA 378i | 53.7 | 67.2 | 1.25 | 0.00067 |
|
| microRNA 412 | 63.6 | 79.4 | 1.25 | 0.00161 |
|
| microRNA 4442 | 379.6 | 480.7 | 1.27 | 0.00020 |
|
| MAX dimerization protein 3 | 31.4 | 39.3 | 1.25 | 0.00149 |
|
| myosin light chain kinase family, member 4 | 177.4 | 270.3 | 1.52 | 0.00019 |
|
| myosin XIX | 65.5 | 80.5 | 1.23 | 0.00169 |
|
| neuropilin (NRP) and tolloid (TLL)-like 2 | 46.8 | 63.8 | 1.36 | 0.00067 |
|
| ninein-like | 35.3 | 42.5 | 1.20 | 0.00250 |
|
| nicotinamide riboside kinase 2 | 211.6 | 924.4 | 4.37 | 2.9E-07 |
|
| neuropilin 1 | 232.1 | 285.1 | 1.23 | 0.00113 |
|
| oxysterol binding protein-like 7 | 66.5 | 85.6 | 1.29 | 2.9E-06 |
|
| phosphodiesterase 4C, cAMP-specific | 44.1 | 55.8 | 1.26 | 0.00093 |
|
| phosphoglycerate kinase 1 | 213.2 | 256.9 | 1.21 | 4.7E-05 |
|
| pyruvate kinase, muscle | 1368.4 | 1792.2 | 1.31 | 3E-05 |
|
| peroxisome proliferator-activated receptor gamma, coactivator 1 alpha | 215.5 | 263.2 | 1.22 | 0.00190 |
|
| protein phosphatase 1, regulatory subunit 3C | 1914.0 | 2377.1 | 1.24 | 0.00066 |
|
| prion protein 2 (dublet) | 31.7 | 42.7 | 1.35 | 0.00121 |
|
| protein C (inactivator of coagulation factors Va and VIIIa) | 40.7 | 49.0 | 1.20 | 0.00164 |
|
| peroxidasin homolog (Drosophila) | 44.0 | 54.8 | 1.25 | 0.00159 |
|
| ribosomal protein L13 pseudogene 5 | 68.3 | 95.5 | 1.40 | 6.1E-05 |
|
| sodium channel, voltage-gated, type IV, beta subunit | 63.9 | 78.2 | 1.22 | 0.00253 |
|
| splicing factor 3a, subunit 3, 60 kDa | 244.4 | 459.9 | 1.88 | 1.9E-05 |
|
| serum/glucocorticoid regulated kinase 1 | 53.9 | 72.7 | 1.35 | 0.00085 |
|
| signal-induced proliferation-associated 1 like 2 | 69.3 | 88.1 | 1.27 | 0.00068 |
|
| solute carrier family 18, subfamily B, member 1 | 60.2 | 74.4 | 1.24 | 0.00037 |
|
| solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 | 32.7 | 39.4 | 1.21 | 0.00041 |
|
| solute carrier family 25, member 30 | 383.6 | 527.5 | 1.37 | 0.00176 |
|
| small nucleolar RNA, H/ACA box 80B | 61.5 | 77.3 | 1.26 | 0.00110 |
|
| small nucleolar RNA, C/D box 115-1 | 170.2 | 245.5 | 1.44 | 0.00077 |
|
| small nucleolar RNA, C/D box 115-11 | 172.0 | 275.4 | 1.60 | 0.00120 |
|
| small nucleolar RNA, C/D box 115-12 | 172.0 | 275.4 | 1.60 | 0.00120 |
|
| small nucleolar RNA, C/D box 115-20 | 95.6 | 155.5 | 1.63 | 0.00018 |
|
| small nucleolar RNA, C/D box 115-22 | 160.9 | 246.9 | 1.53 | 0.00224 |
|
| small nucleolar RNA, C/D box 115-39 | 181.2 | 274.1 | 1.51 | 0.00017 |
|
| small nucleolar RNA, C/D box 115-42 | 167.4 | 266.3 | 1.59 | 0.00137 |
|
| small nuclear ribonucleoprotein polypeptide N | 30.7 | 39.9 | 1.30 | 0.00097 |
|
| syntrophin, beta 1 (dystrophin-associated protein A1, 59 kDa, basic component 1) | 103.2 | 126.2 | 1.22 | 0.00190 |
|
| sterol regulatory element binding transcription factor 1 | 38.8 | 48.2 | 1.24 | 0.00092 |
|
| synaptotagmin XI | 65.2 | 80.6 | 1.24 | 0.00083 |
|
| transmembrane protein 70 | 78.1 | 104.4 | 1.34 | 0.00026 |
|
| transmembrane inner ear | 49.7 | 60.4 | 1.22 | 0.00124 |
|
| tryptase alpha/beta 1 | 51.9 | 63.5 | 1.22 | 0.00072 |
|
| T cell receptor beta variable 5-6 | 68.6 | 88.2 | 1.29 | 0.00014 |
|
| zinc finger, CCHC domain containing 9 | 65.5 | 102.3 | 1.56 | 8.1E-07 |
|
| zinc finger protein 700 | 28.8 | 34.9 | 1.21 | 0.00151 |
|
| zinc finger protein 91 | 126.0 | 167.5 | 1.33 | 0.00041 |
Seventy-three genes that were significantly down-regulated after 6-week HIIT.
| Gene symbol | Gene description | Expression value | Fold change | ||
|---|---|---|---|---|---|
| Before | After | ||||
|
| aminoadipate-semialdehyde synthase | 167.2 | 128.6 | 0.77 | 0.00022 |
|
| alcohol dehydrogenase, iron containing, 1 | 382.8 | 305.8 | 0.80 | 0.00018 |
|
| aldehyde dehydrogenase 2 family (mitochondrial) | 249.8 | 178.3 | 0.71 | 2.27E-06 |
|
| aldehyde dehydrogenase 6 family, member A1 | 130.0 | 103.2 | 0.79 | 0.00027 |
|
| ankyrin repeat and SOCS box containing 15 | 542.1 | 378.8 | 0.70 | 9.14E-07 |
|
| UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 | 120.3 | 80.9 | 0.67 | 9.89E-05 |
|
| chromosome 3 open reading frame 26 | 70.7 | 54.3 | 0.77 | 0.00012 |
|
| chromosome 8 open reading frame 22 | 2864.8 | 2091.7 | 0.73 | 0.00074 |
|
| cell adhesion molecule 2 | 54.7 | 42.8 | 0.78 | 3.48E-04 |
|
| coiled-coil domain containing 141 | 45.9 | 36.3 | 0.79 | 0.00184 |
|
| CD38 molecule | 287.3 | 224.0 | 0.78 | 0.00139 |
|
| 24-dehydrocholesterol reductase | 112.4 | 83.6 | 0.74 | 7.05E-06 |
|
| dimethylglycine dehydrogenase | 56.2 | 43.8 | 0.78 | 0.00041 |
|
| EFR3 homolog A (S. cerevisiae) | 458.1 | 364.8 | 0.80 | 1.13E-04 |
|
| epidermal growth factor receptor | 128.2 | 101.5 | 0.79 | 7.09E-05 |
|
| erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) | 183.4 | 144.8 | 0.79 | 0.00058 |
|
| eyes absent homolog 1 (Drosophila) | 143.1 | 111.0 | 0.78 | 1.62E-05 |
|
| family with sequence similarity 126, member A | 162.7 | 114.5 | 0.70 | 1.01E-03 |
|
| F-box protein 48 | 80.1 | 60.8 | 0.76 | 0.00267 |
|
| uncharacterized LOC378805 | 149.3 | 102.7 | 0.69 | 2.56E-04 |
|
| GATS protein-like 1 | 423.2 | 336.8 | 0.80 | 0.00011 |
|
| glutamic pyruvate transaminase (alanine aminotransferase) 2 | 143.9 | 106.6 | 0.74 | 0.00017 |
|
| histone cluster 2, H2ac | 1263.4 | 957.1 | 0.76 | 0.00175 |
|
| hematological and neurological expressed 1 | 61.1 | 48.3 | 0.79 | 4.14E-05 |
|
| heat shock 27 kDa protein 1 | 1910.4 | 1494.8 | 0.78 | 8.53E-05 |
|
| heat shock 27 kDa protein 3 | 271.0 | 211.9 | 0.78 | 0.00019 |
|
| interferon-induced protein with tetratricopeptide repeats 1 | 56.0 | 41.0 | 0.73 | 0.00012 |
|
| interleukin 17D | 119.3 | 94.1 | 0.79 | 0.00030 |
|
| interleukin 32 | 82.0 | 55.0 | 0.67 | 5.80E-05 |
|
| kinesin family member 1B | 437.7 | 343.4 | 0.78 | 0.00028 |
|
| leucine-rich, glioma inactivated 1 | 77.2 | 57.5 | 0.75 | 0.00036 |
|
| leucine-rich repeat containing G protein-coupled receptor 5 | 360.0 | 214.3 | 0.60 | 0.00083 |
|
| leiomodin 1 (smooth muscle) | 76.3 | 58.9 | 0.77 | 4.23E-05 |
|
| uncharacterized LOC100128560 | 56.2 | 37.5 | 0.67 | 0.00207 |
|
| uncharacterized LOC100188947 | 67.1 | 45.2 | 0.67 | 0.00103 |
|
| uncharacterized LOC100505769 | 100.8 | 78.9 | 0.78 | 0.00242 |
|
| uncharacterized LOC100506338 | 75.9 | 60.0 | 0.79 | 1.10E-04 |
|
| uncharacterized LOC646903 | 172.2 | 123.4 | 0.72 | 0.00016 |
|
| microfibrillar-associated protein 4 | 209.4 | 152.8 | 0.73 | 0.00167 |
|
| microRNA 4681 | 65.3 | 51.6 | 0.79 | 4.59E-05 |
|
| MAP kinase interacting serine/threonine kinase 2 | 287.6 | 221.2 | 0.77 | 0.00017 |
|
| myostatin | 139.8 | 73.6 | 0.53 | 6.92E-06 |
|
| metallothionein 1× | 1524.8 | 1169.2 | 0.77 | 0.00108 |
|
| myosin, heavy chain 1, skeletal muscle, adult | 4283.1 | 2788.7 | 0.65 | 0.00233 |
|
| myosin light chain kinase 2 | 701.4 | 534.4 | 0.76 | 0.00148 |
|
| myomesin family, member 3 | 282.3 | 190.2 | 0.67 | 5.58E-05 |
|
| NIMA (never in mitosis gene a)- related kinase 10 | 145.5 | 108.4 | 0.74 | 9.22E-05 |
|
| nebulin-related anchoring protein | 4720.4 | 3508.3 | 0.74 | 1.91E-06 |
|
| 5′-nucleotidase, cytosolic II | 413.8 | 311.6 | 0.75 | 0.00077 |
|
| nucleoporin 160 kDa | 84.1 | 66.5 | 0.79 | 5.87E-04 |
|
| 3-oxoacid CoA transferase 1 | 115.0 | 79.9 | 0.70 | 0.00101 |
|
| poly(A) binding protein interacting protein 2B | 517.1 | 382.1 | 0.74 | 0.00039 |
|
| PDZ and LIM domain 3 | 2003.3 | 1553.8 | 0.78 | 0.00012 |
|
| profilin 2 | 243.7 | 189.8 | 0.78 | 9.41E-05 |
|
| polymerase (RNA) II (DNA directed) polypeptide J, 13.3 kDa | 109.9 | 78.1 | 0.71 | 0.00026 |
|
| protein kinase, AMP-activated, gamma 3 non-catalytic subunit | 194.4 | 145.4 | 0.75 | 0.00035 |
|
| pygopus homolog 1 (Drosophila) | 129.5 | 100.3 | 0.77 | 0.00051 |
|
| splicing factor 3a, subunit 1, 120 kDa | 129.0 | 103.0 | 0.80 | 1.08E-04 |
|
| SH3 domain containing ring finger 2 | 104.6 | 75.9 | 0.73 | 6.20E-05 |
|
| solute carrier family 1 (glial high affinity glutamate transporter), member 3 | 61.7 | 49.3 | 0.80 | 0.00142 |
|
| solute carrier family 25 (pyrimidine nucleotide carrier), member 33 | 147.8 | 113.2 | 0.77 | 0.00201 |
|
| SLIT and NTRK-like family, member 4 | 70.5 | 52.8 | 0.75 | 0.00243 |
|
| smoothelin-like 1 | 318.2 | 184.2 | 0.58 | 4.52E-04 |
|
| transmembrane protein 47 | 544.1 | 433.1 | 0.80 | 0.00039 |
|
| tumor protein p63 | 136.6 | 90.8 | 0.67 | 8.80E-04 |
|
| TSC22 domain family, member 1 | 185.1 | 142.2 | 0.77 | 0.00034 |
|
| unc-13 homolog B (C. elegans) | 194.8 | 155.9 | 0.80 | 0.00036 |
|
| unc-13 homolog C (C. elegans) | 61.8 | 48.2 | 0.78 | 0.00132 |
|
| WW domain binding protein 11 | 94.3 | 74.5 | 0.79 | 0.00121 |
|
| WD repeat domain 5B | 50.8 | 40.6 | 0.80 | 0.00092 |
|
| Yip1 domain family, member 7 | 295.9 | 235.9 | 0.80 | 0.00055 |
|
| zinc finger protein 36, C3H type, homolog (mouse) | 118.9 | 94.1 | 0.79 | 0.00023 |
|
| zinc finger protein 844 | 65.9 | 51.8 | 0.79 | 0.00065 |
Figure 2The expression of CARNS1 (a), FGF6 (b), MYLK4 (c), PGK1 (d), PPP1R3C (e), and SGK1 (f) genes in the skeletal muscle before and after HIIT (n = 11). The mRNA levels of the six genes were determined by quantitative PCR and significantly increased after the HIIT. The bars represent means and SDs. The B2M mRNA was used as an internal control. *P < 0.05 vs. before-HIIT values.
Figure 3Representative immunoblotting image (a) and protein expression levels of CARNS1 (b), FGF6 (c), MYLK4 (d), PGK1 (e), PPP1R3C (f), SGK1 (g), and PPARGC1A (h) in the skeletal muscle before and after HIIT (n = 11). CARNS1, MYLK4, PPP1R3C, SGK1, and PPARGC1A levels significantly increased after the HIIT, while those of FGF6 and PGK1 did not change. The bars represent means and SDs. A representative western blot is shown. β-actin protein was used as an internal control. *P < 0.05 vs. before-HIIT values. Full image of the gels are presented in Supplemental Figure S1.
Figure 4Enzyme activities of CS (a) and PFK (b) (n = 11). The activities of CS and PFK significantly increased after the HIIT. The bars represent means and SDs. *P < 0.05 vs. before-HIIT values.